CLN Article

Proposed CLIA changes would weaken standards for high-complexity lab leadership

iStock-2222457366

A new proposed rule from the Centers for Medicare and Medicaid Services (CMS) would reduce the minimum qualifications needed to direct laboratories that perform the most advanced and essential laboratory testing. According to CMS, changes would provide flexibility, reduce regulatory burden, and help with workforce shortages. But several provisions would remove independent safeguards that determine whether laboratory directors have the knowledge and competence required to oversee complex testing that millions of patients depend on every day.

The rule, CMS-3478-P, would not only update personnel provisions but also would recommend broad changes to CLIA. The personnel provisions in particular raise serious concerns for laboratory professionals and the patients they serve. CMS proposes eliminating the requirement that doctoral scientists directing high-complexity laboratories hold a Department of Health and Human Services (HHS)-approved board certification. Under the proposal, a doctoral scientist could qualify with either 1 year of experience directing or supervising high-complexity testing or 20 continuing education (CE) hours covering laboratory director responsibilities.

However, board certification for laboratory directors proves much more than the fact that someone has spent time in a supervisory position. Importantly, it provides an independent assessment of specialized knowledge and competence across laboratory medicine. Experience remains important, but it does not, in itself, show that a candidate has mastered the breadth of knowledge required to direct a high-complexity laboratory.  

Laboratory directors’ expertise is especially important as medicine is transformed by artificial intelligence (AI). ADLM has urged policymakers to ensure that emerging AI tools remain subject to the same professional expertise, quality systems, validation, and monitoring standards that apply to laboratory testing. Effective oversight requires qualified laboratory professionals who understand laboratory methods, data, validation, and sources of error. As AI becomes more deeply integrated into laboratory medicine, maintaining that expertise becomes more important.

ADLM is advocating for CMS to retain the HHS-approved board-certification requirement for doctoral high-complexity laboratory directors and reconsider the proposed experience and CE alternatives. Modernizing CLIA should strengthen the law’s ability to protect patients as laboratory medicine changes; it should not undermine standards for those entrusted to lead its most complex work.

ADLM holds congressional briefing on ethical and effective use of healthcare AI

On October 13, the Association for Diagnostics & Laboratory Medicine held a congressional briefing on Capitol Hill to discuss the policy changes needed to ensure that healthcare artificial intelligence (AI) is used judiciously and ethically and benefits all patients, especially children.

AI is becoming an integral part of American healthcare. At the briefing, moderator Dennis J. Dietzen, PhD, chair of pathology and laboratory medicine at Phoenix Children’s Hospital, discussed how this revolutionary new technology is rapidly changing how healthcare organizations manage their operations, analyze data, and diagnose disease. Because clinical laboratories generate approximately 80% of the data used to inform medical decisions, laboratory medicine is at the center of efforts to harness AI to improve patient care.

Although these developments hold much promise, there is still much to be done. Congress needs to put in place a regulatory framework that ensures healthcare AI is used safely and responsibly, while maximizing its benefits and limiting its potential shortcomings.

The briefing featured leading experts in laboratory medicine, including speakers Sarah Wheeler, PhD, clinical pathology medical director at the University of Pittsburgh Medical Center Children’s Hospital of Pittsburgh, and Stephen Master, MD, PhD, vice chair for innovation in the department of pathology and laboratory medicine at Children’s Hospital of Philadelphia.

Wheeler discussed the differences between rule-based AI, which follows an explicit set of rules written by humans, versus generative AI, and the challenges that arise from the different outputs that generative AI gives.

AI needs more than just lab results to function well, Wheeler said. It needs the expertise of laboratory professionals who are adequately provided with the context behind those results.

Master discussed examples of variables that can influence the accuracy of AI healthcare tools in laboratory medicine. One variable is the instrument or manufacturer used to generate test results. Many labs still produce different results depending on the instrument and manufacturer. This can influence how AI healthcare tools report test results.

Another variable is the demographic data that an AI algorithm was trained with. If it was trained with data from adult patients, can it adequately address the test results of pediatric patients? Given these and many more variables, laboratories need transparency from developers on the data used to train AI healthcare tools.

The Senate passes Health Care Cybersecurity and Resilience Act

The Senate passed the Health Care Cybersecurity and Resilience Act of 2026 on September 30 by unanimous consent. This bipartisan bill aims to improve coordination between the Department of Health and Human Services (HHS) and the Cybersecurity and Infrastructure Security Agency to strengthen responses to cyberattacks in healthcare.

Clinical laboratories operate within the healthcare data ecosystem that this legislation is trying to safeguard; they handle protected health information and rely on digital systems to process and communicate test results. The bill’s cybersecurity requirements and provisions therefore have direct implications for clinical labs, where a breach or system disruption can affect both patient data and laboratory operations.  

If made law, the bill would require entities regulated by the Health Insurance Portability and Accountability Act (HIPAA) to make significant investments in cybersecurity infrastructure, including implementing multifactor authentication, encryption, penetration testing, and alignment with national frameworks, such as the National Institute of Standards and Technology Risk Management Framework. These obligations would call for a thorough review of existing compliance programs.

The bill would also implement a deadline for HHS — 1 year after the legislation becomes law — to promulgate regulations that implement the safe harbor for “recognized security practices.” Originally enacted in January 2021 as an amendment to the Health Information Technology for Economic and Clinical Health Act, the safe harbor provision requires HHS to consider whether a HIPAA-regulated entity implemented recognized security practices for at least the prior 12 months when determining fines, the length and disposition of audits, and other remedies for HIPAA violations.  

The bill would also require annual reporting by HHS to Congress on its consideration of recognized security practices in HIPAA enforcement. For organizations proactively implementing recognized security practices, the safe harbor could potentially mitigate penalties in the event of an HHS investigation, audit, or cybersecurity incident.

Although the bill must still clear additional legislative hurdles before becoming law, its bipartisan advancement out of committee signals that HIPAA-regulated entities could benefit from proactively assessing gaps in their current cybersecurity posture, breach notification procedures, and incident response plans now, rather than waiting for final enactment of the law. 

Read the full November-December issue of CLN.

Advertisement

Advertisement